Citizens raised the firm’s price target on GH Research (GHRS) to $42 from $39 and keeps an Outperform rating on the shares. GH Research reported Q4 results highlighting continued progress for GH001, with the FDA lifting the clinical hold and the company now working with regulators to finalize a Phase 3 trial design targeting a 2026 study start, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GHRS:
- GH Research: Phase 3 Readiness, Expanding Indications, and Valuation Upside Reinforce Buy Rating
- Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
- GH Research Posts 2025 Results as TRD Drug GH001 Clears Key Phase 2b Milestone
- GH Research reports FY25 EPS (79c), consensus (82c)
- Psychedelic: Analyst raises Compass, Definium, GH Research price targets